Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

Vertex has begun a full-court press for Journavx, enlisting NBA All-Star Jayson Tatum to discuss his use of the new ...

With the business potentially at an important milestone, we thought we'd take a closer look at Vertex, Inc.'s (NASDAQ:VERX) future prospects. Vertex, Inc., together with its subsidiaries, provides ...

Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends ...

If you have been eyeing Vertex Pharmaceuticals and wondering whether it is the right time to buy, sell, or simply hold tight, ...

If past performance guaranteed future success, Vertex Pharmaceuticals (NASDAQ: VRTX) would be one of the best biotech stocks to invest in. The drugmaker has consistently outperformed the broader ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vertex AI is a comprehensive machine learning platform by Google Cloud, provides an all-inclusive suite of tools and resources for the creation, deployment, and customization of machine learning ...

Pfizer's overall business still looks robust enough to recover, despite upcoming headwinds. The stock's forward price-to-earnings (P/E) ratio of 7.7 appears dirt cheap when compared to the industry ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle ...